Consider ZOLADEX for your appropriate patients with endometriosis. ZOLADEX is a gonadotropin-releasing hormone (GnRH) agonist indicated for use in the management of endometriosis, including pain relief and reduction of endometriotic lesions for the duration of therapy. For the management of endometriosis, the recommended duration of administration is 6 months for women 18 years of age and older. There are no clinical data on the effect of benign gynecological conditions with ZOLADEX for periods in excess of 6 months. Retreatment cannot be recommended because safety data for retreatment are not available.
ZOLADEX is also indicated for use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding. The dosing recommendation is one or two depots, with each depot given 4 weeks (28 days) apart. If one depot is administered, surgery should be performed at 4 weeks. When two depots are administered, surgery should be performed within 2 to 4 weeks following administration of the second depot.
ZOLADEX 3.6 mg should be administered subcutaneously every 28 days into the anterior abdominal wall below the navel line, using an aseptic technique. While a delay of a few days is permissible, every effort should be made to adhere to the 28-day schedule. Instructions for proper administration are demonstrated in the administration video.
The most frequently reported adverse reactions were related to hypoestrogenism. The most commonly reported adverse reactions with ZOLADEX in clinical trials for endometriosis were: hot flashes (96%), vaginitis (75%), headache (75%), decreased libido (61%), emotional lability (60%), depression (54%), sweating (45%), acne (42%), breast atrophy (33%), seborrhea (26%), and peripheral edema (21%).
There are 3 easy ways to order ZOLADEX with the Direct Purchase Program. Choose the ordering method that best suits your needs.
ZOLADEX is ready to use. You do not need to refrigerate or premix ZOLADEX prior to administering the depot.
If you have other questions about ZOLADEX, please contact AstraZeneca, 8:00 AM to 6 PM, EST at 1-800-236-9933.
See and share the answers to frequently asked questions about ZOLADEX that patients may ask. These answers can help patients understand what ZOLADEX is, how it works, and what they may expect from therapy with ZOLADEX for endometriosis. Go to the patient FAQs.
The following list of resources is provided as a convenience to you. AstraZeneca takes no responsibility for the content of, or services provided by, these resources and makes no representation as to the accuracy or completeness of any information provided by these resources. AstraZeneca shall have no liability for any damage or injuries of any kind arising from the information provided by the resources listed. The descriptions of the organizations are all directly from their respective Web sites.
Professional resources to support you
American Congress of Obstetricians and Gynecologists is the nation’s leading group of professionals providing health care for women. It is a private, voluntary, nonprofit membership organization. The ACOG updated guideline on diagnosis and treatment of endometriosis is available at the American Family Physician Web site: www.aafp.org/afp/2011/0101/p84.html.
Office of Communications and Knowledge Transfer
The Agency for Healthcare Research and Quality’s mission is to produce evidence to make health care safer, higher quality, more accessible, equitable, and affordable, and to work within the US Department of Health and Human Services and with other partners to make sure that the evidence is understood and used. AHRQ guidelines for the management of endometriosis are available at: www.guideline.gov/content.aspx?id=16327.
Resources to help you support your patients
The Endometriosis Foundation of America strives to increase disease recognition, provide advocacy, facilitate expert surgical training, and fund landmark endometriosis research. It places particular emphasis on the critical importance of early diagnosis and effective intervention while providing education to the next generation of medical professionals and their patients.
Endometriosis.org delivers up-to-date, evidence-based information and news about endometriosis, and provides knowledge to empower women to make informed decisions about their treatment options. There is no contact information for this organization. The site is an information resource.
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.